IGC Pharma, Inc. is a clinical-stage company, which is engaged in developing treatments for Alzheimer’s disease. The Company’s flagship drug, IGC-AD1, is an investigational drug tackles agitation, a major burden for patients and caregivers by addressing neuroinflammation. The Company operates through two segments: Life Sciences Segment and Infrastructure Segment. Its TGR-63 has demonstrated its potential to disrupt the progression of Alzheimer’s by targeting Aβ plaques, a key disease hallmark. The Company’s IGC-1C represents a potential breakthrough by targeting tau protein and neurofibrillary tangles, aiming to modify the disease course. Its IGC-M3 focuses on early intervention by inhibiting Aβ plaque formation, potentially slowing cognitive decline. Its LMP is designed to target multiple hallmarks of Alzheimer’s disease, including Aβ plaques and neurofibrillary tangles for a comprehensive therapeutic effect. It seeks to leverage artificial intelligence (AI) for Alzheimer's research.

• Revenue in USD (TTM)1.06m
• Net income in USD-13.30m
• Incorporated2005
• Employees67.00

• Location
  IGC Pharma Inc2405 York Road, Suite 201LUTHERVILLE-TIMONIUM 21093-2264United StatesUSA
• Phone+1 (301) 983-0998
• Fax+1 (240) 465-0273
• Websitehttps://igcpharma.com/